[ad_1] SHANGHAI, MIDDLETOWN, Del. and MUNICH, Nov. 19, 2025 /PRNewswire/ — WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global […]
Tag: WuXi AppTec
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
[ad_1] Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY […]
Le site de Couvet de WuXi AppTec reçoit la médaille d’argent EcoVadis 2024
[ad_1] COUVET, Suisse, 15 novembre 2024 /PRNewswire/ — WuXi AppTec, une entreprise mondiale qui fournit un large portefeuille de services de R&D et de fabrication aux entreprises des secteurs pharmaceutique et des sciences de la […]
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
[ad_1] SHANGHAI, Oct. 29, 2024 /PRNewswire/ — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded […]
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
[ad_1] Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year Net Profit Attributable […]
